As part of its long-term sustainability commitment, Ypsomed has joined the Science Based Targets initiative (SBTi), targeting net zero emissions across its entire value chain by 2040
Research Context In controlled research environments, Retatrutide has been examined in relation to: Triple-receptor signaling models: Investigation of GLP-1, GIP, and glucagon pathway interactions
These may have mild metabolic effects when taken orally, but there is no scientific evidence that they work through a patch
No en todos los casos
Before taking GLP-1s, there also needs to be in-depth conversations about what you're signing up for, the risks and benefits, and the long-term plan for treatment
2022 Jensen AB, Renstrm F, Aczl S et al (2023) Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study